Effect of radium-223 dichloride (Ra-223) on hospitalisation: An analysis from the phase 3 randomised Alpharadin in Symptomatic Prostate Cancer Patients (ALSYMPCA) trial-Reference-Cited by-同舟云学术

Effect of radium-223 dichloride (Ra-223) on hospitalisation: An analysis from the phase 3 randomised Alpharadin in Symptomatic Prostate Cancer Patients (ALSYMPCA) trial

Published:2017-01 Issue: Volume:71 Page:1-6
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Parker Christopher,Zhan Lin,Cislo Paul,Reuning-Scherer Jonathan,Vogelzang Nicholas J.,Nilsson Sten,Sartor Oliver^ORCID,O'Sullivan Joe M.,Coleman Robert E.

Funder

Bayer Healthcare Pharmaceuticals Inc.

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference14 articles.

1. The clinical and economic impacts of skeletal-related events among medicare enrollees with prostate cancer metastatic to bone;McDougall;Oncologist,2016

2. Measurement of skeletal related events in SEER-Medicare: a comparison of claims-based methods;Aly;BMC Med Res Methodol,2015

3. Health resource utilization associated with skeletal-related events in patients with advanced prostate cancer: a European subgroup analysis from an observational, multinational study;Bahl;J Clin Med,2014

4. Healthcare utilization and costs associated with skeletal-related events in prostate cancer patients with bone metastases;Hagiwara;Prostate Cancer Prostatic Dis,2013

Cited by 47 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Targeted Radiopharmaceutical Therapy for Bone Metastases;Seminars in Nuclear Medicine;2024-07

2. Radiation Therapies in Cancer;Therapeutic Approaches in Cancer Treatment;2023

3. Case Study #8: Alpha-Therapy with Radium-223 Dichloride for Metastatic Castration-Resistant Prostate Cancer;Radiopharmaceutical Therapy;2023

4. A Treatment Paradigm Shift: Targeted Radionuclide Therapies for Metastatic Castrate Resistant Prostate Cancer;Cancers;2022-09-01

5. Radium-223 for Metastatic Castrate-Resistant Prostate Cancer;Practical Radiation Oncology;2022-07